Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
Journal of Hepatology — Yeung A, Palmateer NE, Dillon JF, et al. | October 11, 2021
Researchers sought to report on the extent of reinfection following scale-up of highly-effective direct-acting antivirals (DAAs) for hepatitis C virus (HCV) among people who inject drugs (PWID) in Scotland.
Follow-up was performed of a retrospective cohort of PWID who initiated treatment between 2000-2018 and attained a sustained virological response (SVR) for reinfection to December 2019.
Researchers identified data concerning 5,686 SVRs among 5,592 PWID, 4,126 of whom (73%) had an HCV RNA or antigen test post-SVR.
The early phase of treatment scale-up with direct-acting antivirals showed an increase in HCV reinfection rates among PWID.
Groups at high risk of reinfection, considered vital for elimination, are reached in community-based treatment pathways.
There were low levels of retesting for HCV beyond the first year following successful treatment.
In the early phase of treatment scale-up, substantial numbers of HCV reinfections may have not been detected.
Concerted effort to ensure prompt diagnosis of reinfection needs to be integral to national strategies scaling up DAAs among PWID.
Read the full article on Journal of Hepatology